Ting Therapeutics Advances TT004 into Phase Ib Clinical Trials as a Potential Cisplatin Chemoprotective Therapy

Oct 23, 2026

San Diego, California Oct 22, 2026 (Issuewire.com) - Ting Therapeutics Advances TT004 into Phase Ib Clinical Trial as a Potential Chemoprotective Therapy for Cisplatin-Treated Patients

  • China IND Approved;
  • Phase Ib Trial Set to Begin Recruiting Patients at Eye and ENT Hospital of Fudan University in Shanghai

Ting Therapeutics, Inc., a biotechnology company developing therapies for treatment-related tissue injury, today announced that its lead candidate, TT004, has received IND approval in China and is advancing into Phase Ib clinical development as a potential chemoprotective therapy for patients receiving cisplatin chemotherapy.

Cisplatin is a highly effective cancer treatment, but its toxicities can substantially limit therapy. Approximately 40% of patients discontinue or modify chemotherapy because of treatment-related toxicities. Cisplatin can also cause permanent hearing loss in up to 80% of patients and acute kidney injury in approximately 30% of patients.

TT004 is designed to protect normal tissues from cisplatin toxicity while preserving its anticancer activity. In preclinical studies, TT004 increased survival following cisplatin exposure three-fold and reduced cisplatin-induced hearing loss and kidney injury by approximately 70%, without compromising cisplatin's anticancer effects.

"These findings support our vision of TT004 as a chemoprotective therapy that could improve the tolerability of cisplatin while maintaining its anticancer efficacy," said Jian Zuo, PhD, Co-Founder and CEO of Ting Therapeutics. "Our goal is to reduce the suffering caused by cisplatin treatment-related toxicities, help more patients receive and complete effective chemotherapy, and improve their long-term quality of life."

Ting Therapeutics recently licensed its China rights for TT004 to Rising Dragon, a Chinese biotechnology company, for development in China. The companies jointly developed TT004 as an oral tablet and obtained IND approval from China's Center for Drug Evaluation (CDE) for first-in-human clinical evaluation.

The Phase Ib trial, conducted in collaboration with oncologists and otolaryngologists at Eye and ENT Hospital of Fudan University in Shanghai, will evaluate the safety and tolerability of oral TT004 administered with standard-of-care cisplatin chemotherapy in patients with head and neck cancer. The study has received institutional ethics approval and is preparing to initiate patient recruitment.

TT004's protective effects have been demonstrated only in preclinical models and have not yet been shown in humans. This trial is the first clinical evaluation of TT004 and an important step toward determining whether these effects can be translated to cancer patients.

About Ting Therapeutics

Founded in 2018, Ting Therapeutics, Inc. develops novel and repurposed therapeutics to prevent and treat hearing loss and other treatment-related tissue injuries. The Company's pipeline targets hearing loss associated with chemotherapy, noise exposure, antibiotics, aging, and other causes.

Contact:
Jian Zuo, PhD, Co-Founder & CEO
Ting Therapeutics, Inc.
6868 Nancy Ridge Dr., San Diego, CA 92121
[email protected]

Ting Therapeutics

 

Source :Ting Therapeutics, Inc.

This article was originally published by IssueWire. Read the original article here.

More News

article.head.headline
Oct 23, 2026
40 Travel Products Under $20 That Are Worth Every Penny

These silicone bottle covers and these clear waterproof shoe bags are things you get yourself now so you can thank yourself later. View Entire Post ›

article.head.headline
Oct 23, 2026
Get Ready To Be Called "Mary Poppins" — 27 Teensy Tiny Travel-Sized Items That'll Fit In Your Purse

You’re always gonna be prepared. View Entire Post ›

article.head.headline
Oct 23, 2026
Build Your Dream Late Night Road Trip And We'll Expose Your Most Powerful Hidden Talent

Are you secretly the chaos whisperer? View Entire Post ›

article.head.headline
Oct 23, 2026
Brunello Cucinelli on director Giuseppe Tornatore’s documentary about his life

When designer and entrepreneur Brunello Cucinelli announced that he would be releasing a documentary about his life directed by Oscar winner Giuseppe Tornatore, it caught many by surprise. Titled Brunello, Il Visionario Garbato (Brunello: The Gracious Visionary), the film combines interviews and real-life footage with re-enactments to show Cucinelli’s childhood and his early days as a striving entrepreneur and designer, long before he became known as the “king of cashmere”. Works of this type...

article.head.headline
Oct 22, 2026
'I'm 96 and have 15 million followers': The grannies taking over TikTok

Grandma Droniak, Nonna Gracie, Viv Truran and Barbara Costello have all found fame on social media in their later years.

article.head.headline
Oct 22, 2026
How AI microdrama Yanbian Qingmei is driving interest in an ancient Chinese calligrapher

While the Tang dynasty (618-907) is synonymous with a golden age of Chinese arts and culture, its glittering reign was fractured by one of history’s most devastating civil wars. Today, the life and work of the revered Tang dynasty calligrapher Yan Zhenqing, a key figure in that 1,200-year-old tragedy, are capturing the attention of millions, partly thanks to an AI microdrama. The series titled Yanbian Qingmei, which roughly translates to Green Plums by the Inkstone, has accumulated more than 100...

article.head.headline
Oct 22, 2026
How Cantopop diva Paula Tsui defined an era with her contralto voice and polka dot dresses

This is the 88th instalment in a biweekly series profiling major Hong Kong pop culture figures of recent decades. With her signature polka dot gowns, umbrella skirts and velvet-deep contralto voice that defied the high-pitched norms of her era, Paula Tsui Siu-fung did not just become a Cantopop superstar; she defined the very archetype of the Hong Kong diva. Over a career spanning more than five decades, her record-shattering live performances and unprecedented album sales have cemented her...

article.head.headline
Oct 22, 2026
Grid operator says lights will stay on this winter after concerns

The assurance from the National Energy System Operator comes amid concern from its engineers about their ability to ensure adequate supply.

article.head.headline
Oct 22, 2026
L'Oreal says weight loss drugs are impacting beauty and skin care sales

The beauty giant's CEO says the use of GLP-1s is "a very important phenomenon for us".

article.head.headline
Oct 22, 2026
Meet Lily Pearl Black, daughter of country singer Clint Black and actress Lisa Hartman

Clint Black and Lisa Hartman Black celebrated their 35th wedding anniversary on October 20 this year. The country music singer and actress met backstage at Black’s concert on New Year’s Eve in 1990 and tied the knot several months later in 1991. “We strongly believe in communicating,” Hartman told Fox News when asked about the secret behind her long-lasting marriage. “It sounds so simple, but you really, really have to talk everything through. Roy Rogers said to Clint, ‘One piece of advice:...

article.head.headline
Oct 22, 2026
"Scariest Night Of My Life": 34 Unsettling Small Towns That People Have Stopped In, And These Have Convinced Me NEVER To Visit One With A Population Under 1,000

"We reversed out of there as quickly as we could, screaming and certain that we just stumbled upon something we shouldn’t have." View Entire Post ›

article.head.headline
Oct 22, 2026
What Is PHP? Why Are Government and Business Websites Going Offline?

A critical security flaw in the programming language underpinning much of the web has prompted a global rush to patch vulnerable systems.


YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.